Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OTLK
STRONG SELLOutlook Therapeutics, Inc. · Healthcare · United States · $263M · Avg Vol: $16M/d
11
StockRankGet insider-trade alerts
Q
9
V
23
M
57
P/E (TTM)
—
ROE
—
D/E
—
Dividend %
—
Loading 1Y...
PRICE (1Y)-12.7%
SMA 50SMA 200
Close
$1.07
RSI (14)
36.5
52W High
$3.39
From 52W High
0.3%
SCORE BREAKDOWN
Quality
9
ROIC (ROA)
-184.8%*2.9
ROE
—N/A
GP/Assets
-6.5%7.4
Op. Margin
-11006.8%2.1
FCF/Assets
-137.1%0.9
Piotroski
111.4
Int. Cover
-50.0x6.3
D/E Ratio
—N/A
Current Ratio
0.54x2.7
Value
23
P/E (TTM)
—N/A
EV/EBITDA
-3.1x25.0
P/FCF
—N/A
P/B
-5.1x25.0
P/S
788.6x3.1
Div Yield
—N/A
Momentum
57
52W High %
31%9.1
RS 6M
104%97.9
SMA 50/200
1.21x90.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+81%67.6
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$263M
P/E (Forward)
-6.4x
Gross Margin
4.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OTLK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OTLK | Outlook Therapeutics, Inc.(you) | $263M | 11 | STRONG SELL |
| TTRX | Turn Therapeutics Inc. | $254M | 10 | STRONG SELL |
| NMRA | Neumora Therapeutics, Inc. | $276M | 10 | STRONG SELL |
| RNAC | Cartesian Therapeutics, Inc. | $232M | 12 | STRONG SELL |
| TARA | Protara Therapeutics, Inc. | $226M | 12 | STRONG SELL |
| IRD | Opus Genetics, Inc. | $254M | 14 | STRONG SELL |
| LCTX | Lineage Cell Therapeutics, Inc. | $257M | 8 | STRONG SELL |
| FULC | Fulcrum Therapeutics, Inc. | $248M | 14 | STRONG SELL |
| GALT | Galectin Therapeutics Inc. | $229M | 9 | STRONG SELL |
| NBP | NovaBridge Biosciences | $205M | 11 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.6%